Since they were first described in 1993, it was found that recombinant variable fragments (rVHHs) of heavy-chain antibodies (HCAbs) from Camelidae have unusual biophysical properties, as well as a special ability to interact with epitopes that are cryptic for conventional Abs. It has been assumed that in vivo raised polyclonal HCAbs (pHCAbs) should behave in a similar manner than rVHHs; however, this assumption has not been tested sufficiently. Furthermore, our own preliminary work on a single serum sample from a llama immunized with a b-lactamase, has suggested that pHCAbs have no special ability to down-modulate catalytic activity. In this work, we further explored the interaction of pHCAbs from four llamas raised against two microbial enzymes and analyzed it within a short and a long immunization plan. The relative contribution of pHCAbs to serum titer was found to be low compared with that of the most abundant conventional subisotype (IgG 1 ), during the whole immunization schedule. Furthermore, pHCAbs not only failed to inhibit the enzymes, but also activated one of them. Altogether, these results suggest that raising high titer inhibitory HCAbs is not a straightforward strategy -neither as a biotechnological strategy nor in the biological context of an immune response against infection -as raising inhibitory rVHHs.
Introduction
In the last decades, the knowledge about the structure and function of antibodies (Abs) has shown a marked progress. As part of it, several new Ab classes have been described and cataloged as 'non-conventional' because of their structural and biochemical properties. One of the most relevant discoveries in this field is the existence of functional immunoglobulin (Ig) isotypes devoid of light chains, named 'Heavy-Chain Antibodies' (HCAbs) as a consequence of their homodimeric structure. These Abs were first reported by Hamers-Casterman et al. (1993) , and they have been extensively described for all the members of the Camelidae family (dromedaries, camels, llamas, guanacos, vicunas and alpacas; Muyldermans et al., 2001; Nguyen et al., 2002; Su et al., 2002) . In these studies, it was reported that conventional Abs (IgG 1 and IgM) constitute about 60% to 80% of total mass of serum Igs, and HCAbs (IgG 2 and IgG 3 ) the remaining 20% to 40% (De Simone et al., 2008) .
Since the discovery of HCAbs, many researchers have focused their work on the biophysical properties of the recombinant variable fragments (rVHHs) of HCAbs, as well as on their possible biotechnological applications (Saerens et al., 2008; Muyldermans et al., 2009; Doñ a et al., 2010) . Among the unique features that were described, it was found that these rVHHs display an unusually reversible unfolding when exposed to high temperature and denaturing agents -Present address: Cá tedra de Inmunología (48 piso), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, CP1113 Ciudad Autó noma de Buenos Aires, Buenos Aires, Argentina. E-mail: aferrari@ffyb.uba.ar (van der Linden et al., 1999; Pé rez et al., 2001; Ewert et al., 2002) . In addition, it has been reported that the noncanonical structure of complementary determining regions leads to a preferential cleft recognition, allowing rVHHs to interact with epitopes that are cryptic for conventional Abs, similar to the active site of enzymes (Martin et al., 1997; Lauwereys et al., 1998; De Genst et al., 2006) . Therefore, these rVHHs have been proposed as an ideal source of specific small inhibitory molecules.
Although the reports on rVHH's properties are outstanding and have already given us fundamental knowledge for future biomedical technologies, a question arises on whether this inhibitory capacity can also be obtained by raising polyclonal HCAbs (pHCAbs) during in vivo immune responses. This issue has been partially addressed by Lauwereys et al. (1998) , who succeeded in demonstrating enzyme modulation by rVHH fragments for two enzymes (lysozyme and a-amylase); however, it is not clear whether these results may be extrapolated to all the other enzymes, or are a consequence of a special feature of the selected antigens. The relevance of this matter is reinforced by our own preliminary reports concerning b-lactamase activation by pHCAbs from a single serum sample of a llama (Lama glama; Ferrari et al., 2007) .
For the reasons mentioned above, in this work we further explored the interaction between pHCAbs and two microbial enzymes, characterizing this interaction during the time-course of a short and a long immunization schedule. The enzymes that were selected have their active sites buried in clefts (Matagne et al., 1995; Yang et al., 1997; Page et al., 1998) . Both the enzymes belong to families of wellcharacterized proteins, with known sequence and resolved crystallographic structure. In addition, their catalytic activity can be measured by simple methods. The ability to specifically recognize the enzymes and modulate their enzymatic activity in vitro was studied for total serum, the most abundant conventional Ig subisotype (IgG 1 ) and the most abundant HCAb subisotype (IgG 3 ). The properties of these three fractions were followed and compared within the immunization schedule in order to compose a time-dependent profile based on the behavior of specific Abs raised against the enzymes.
Material and methods
Aspartic protease (APM) purification An APM from Mucor miehei was purified from a commercial solid preparation (DSM Food Specialties, Delft, the Netherlands), by size-exclusion chromatography. A solution containing 400 mg/ml of the solid was prepared in phosphate buffered saline (PBS), and 500 ml were loaded into a Sephadex G-150 column (GE Healthcare, Milwaukee, USA) (100 cm 3 1 cm) using PBS as the mobile phase. Fractions of 1 ml were collected, and protein purity was assessed by 12% SDS-PAGE. All fractions containing .95% of APM were pooled, protein concentration was measured using the BCA Protein Assay kit (Pierce Biotechnology Inc., Rockford, IL, USA), and aliquots were stored at 2208C until use.
b-lactamase expression and purification A recombinant Escherichia coli clone with a plasmid encoding for a CTX-M-2 like b-lactamase (CTX-M-2) from Morganella morganii, was kindly provided by Dr Gutkind (Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires). Cloning, expression and purification were performed as previously described (Power et al., 2005; Ferrari et al., 2007) .
Animals and immunization schedules Two adult llamas were inoculated with APM (L1 APM and L2 APM ), and two adult llamas were inoculated with CTX-M-2 (L1 CTX and L2 CTX ). All animal experimentations have been carried out in accordance with the EC Directive 86/609/ European Economic Community for animal experiments, and the Guiding Principles of the Exact and Natural Sciences School, University of Buenos Aires, Argentina.
Preimmune and immune sera were obtained by jugular vein puncture. All the animals were immunized subcutaneously using a mixture of equal parts of the immunogen solution (700 mg of total mass) and Complete Freund Adjuvant. Animals immunized with APM were inoculated once a week, and serum samples were collected at days 0 (preimmune), 8, 29 and 42. Animals immunized with CTX-M-2 were inoculated every 2 weeks and serum samples were collected at days 0 (preimmune), 60, 75, 90, 150, 170 and 215. Serum titration by ELISA The titration of total serum Igs was performed as previously described (Ferrari et al., 2007) . Briefly, 96-well microplates (Nunc Maxisorp, Roskilde, Denmark) were coated with 0.1 mg of purified APM or CTX-M-2 per well, and blocked with 3% non-fat milk diluted in PBS. Coated microplates were incubated for 1 h at 378C with serum samples in twofold dilutions, and then with a peroxidase labeled secondary Ab (Horse Radish Peroxidase goat anti-llama IgG; Bethyl Laboratories Inc., Montgomery, TX, USA) diluted 1/4000 in PBS. Immunoreactivity was developed with O-phenylenediamine 2 mg/ml and H 2 O 2 0.1% v/v during 10 min. Optical density (OD) was measured in a Multiscan EX microplate reader (Thermo Electron Corporation, Massachusetts, USA) and ELISA titers were expressed as the inverse of the dilution of the central value of the sigmoidal curve (EC 50 ).
Purification of llama Igs IgG 1 and IgG 3 were purified from the selected serum samples as previously described (De Simone et al., 2005; Ferrari et al., 2007) , using a HiTrap-protein G column (GE Healthcare, Piscataway, NJ, USA) and low pH elution buffers (pH 3.5 for IgG 3 and pH 2.7 for IgG 1 ). All Ab fractions were neutralized with Tris 1 M, dialyzed against PBS and protein purity was assessed by 10% SDS-PAGE. Samples were stored at 2208C until use. An additional fraction containing total Igs was obtained by serum precipitation with 38% (NH 4 ) 2 SO 4 , and used to assess the modulatory capacity of APM by total Abs; this procedure was performed in order to eliminate non-Ig proteins, as it was demonstrated that serum proteins comprised an interference for the activity modulation assays Modulation of enzymes by llama heavy-chain antibodies of APM (data not shown). Control experiments proved that proteins do not interfere with the activity measurement of CTX-M-2.
Titration of purified Igs Purified IgG 1 and IgG 3 from all animals were titrated as described for the whole sera, starting at 10 mg/ml of Ig concentration, using twofold dilutions.
APM activity modulation assays The enzymatic activity of APM was determined by the hydrolysis of azocasein (Sigma Chemical Co., St Louis, MO, USA) at 378C, as it has been previously described (Bendicho et al., 2002) . Briefly, APM was incubated in the presence of azocasein (5 mg/ml) in acetate buffer 0.1 M pH 5.0, for 90 min at 378C. Non-hydrolyzed azocasein and other proteins were precipitated with 50 ml of 20% trichloroacetic acid and then centrifuged at 10 0003g during 10 min at 48C. To measure the concentration of soluble peptides produced by azocasein hydrolysis, 200 ml of each sample were transferred to a 96-well microplate, and OD at 405 nm was measured using a microplate reader.
The activity modulation capacity of total Igs from serum samples was determined by preincubating APM with a fixed mass of total Igs, composed of different proportions of immune/preimmune Igs obtained by SO 4 (NH 4 ) 2 precipitation. The activity modulation capacity of purified llama subisotypes was determined by preincubating APM with a fixed mass of Igs obtained by affinity chromatography, composed of different proportions of immune/preimmune Igs.
Ig degradation due to APM activity during the experiments was checked by SDS-PAGE at different incubation times, and considered negligible (results not shown).
CTX-M-2 activity modulation assays The enzymatic activity of purified CTX-M-2 was determined by the hydrolysis of cephalothin (Ivax Argentina S.A., Buenos Aires, Argentina) at 378C during 150 s, and measuring UV absorption at 273 nm ðD 273 M ¼ À6300=M=cmÞ in a thermostatized spectrophotometer (Beckman Coulter DU 7400, Fullerton, CA, USA).
The activity modulation capacity of serum samples was determined by preincubating CTX-M-2 with a fixed volume of serum, composed of different proportions of immune/ preimmune sera. The activity modulation capacity of purified llama subisotypes was determined by preincubating CTX-M-2 with a fixed mass of Ig, composed of different proportions of immune/preimmune Igs.
Nonlinear regression analysis of modulation assays Nonlinear regression analyses were performed using GraphPad Prism 4.0 (GraphPad Software, San Diego, CA, USA). A 'one phase exponential decay/association' curve was fitted to residual enzymatic activity data, and two parameters were obtained: the maximum modulation (MM) achieved, and the Ab concentration that produces 50% of MM (Modulatory Capacity 50, MC 50 ). An arbitrary score was calculated for each serum sample, according to expression (1):
This score assigns an arbitrary relative weight to each parameter, compensating their differences in magnitude and units. It was empirically constructed, and it is expected to facilitate the analysis of the modulation assays. The f MW terminus is a correction factor applied to compensate the differences in molecular weight between conventional (f MW 5 1.0) and non-conventional Abs (f MW 5 1.5).
Statistical analyses Titration assays were further analyzed by ANOVA, and a Dunnet post test was performed, comparing each condition v. the condition without immune Igs. Differences were considered significant when P , 0.05.
Results

Antigen purification
Both the antigens were purified as described, and their purity was verified by SDS-PAGE, as shown in Figure 1 . Purity was demonstrated to be at least 95%, as demonstrated by a densitometry analysis.
Serum titration by ELISA All llamas elicited a significant antigen-specific immune response. Serum titers of animals L1 APM and L2 APM began to rise from day 8 until the end of the immunization schedule; titers of L1 CTX and L2 CTX reached a maximum at days 75 (L1 CTX ) or 90 (L2 CTX ), and then decreased to a lower and more stable value until the end of their immunization schedule (Figure 2) . According to these results, three different serum samples from animals L1 CTX and L2 CTX were selected for the catalytic modulation assays, and all serum samples from animals L1 APM and L2 APM were used. All further Ig purification and activity modulation assays were performed with these samples.
Activity modulation assays with total Igs Total Igs precipitated from L1 APM and L2 APM samples produced no significant enzyme modulation, and therefore neither the curve fitting nor the modulatory score could be calculated. On the contrary, serum samples from L1 CTX and L2 CTX had increasing inhibitory power during the schedule (Figure 3) . The modulatory score of both animals immunized with CTX-M-2 had a moderate tendency to increase within the immunization schedule.
Purification and titration of Igs Purification of IgG 1 and IgG 3 was performed as described, and their purity was assessed by SDS-PAGE (Figure 4) . . Curves correspond to activity modulation assays, and were constructed plotting the residual enzymatic activity v. the absolute mass of immune Ig used in the reaction mixture. Total serum Igs were considered to be at a concentration of 10 mg/ml. Bar graphs are the corresponding score values for each curve; error bars represent the standard error, as calculated by the error propagation method.
All fractions were proved to have a purity of at least 95%, as demonstrated by a densitometry analysis. Titrations, as shown in Figures 5 and 6 , indicate that purified IgG 1 and IgG 3 from all animals have increasing titers during the immunization schedule. IgG 1 titers had much higher values than those of IgG 3 in all animals, and its progress pattern resembles the behavior of total Igs. This difference in the relative contribution of each subisotype is reinforced by the fact that normal serum IgG 3 concentration, although being the most abundant HCAb isotype, has been previously reported to be 5 to 10 times lower than that of IgG 1 (De Simone et al., 2008) . Activity modulation assays with purified Igs IgG 1 from both L1 APM and L2 APM produced a positive modulation of APM activity ( Figure 7) ; on the contrary, IgG 3 had no effect on the enzyme. In contrast, purified IgG 1 from animals L1 CTX and L2 CTX produced an intense negative modulation of CTX-M-2 activity, as shown in Figure 8 . This modulation had a progress pattern with less intense values than that of serum, and a maximum at days 75 (L1 CTX ) or 90 (L2 CTX ). Purified IgG 3 from both animals immunized with CTX-M-2, not only failed to produce a negative modulation of the enzyme, but also induced a strong positive modulation of its catalytic activity. This positive modulation had a maximum at days 60 (L1 CTX ) or 90 (L2 CTX ), and then decreased to a slight negative modulation.
Discussion
Previous reports have stated that rVHHs have a special ability to interact with certain epitopes that are cryptic to conventional Abs, similar to the active site of enzymes. These reports also show that because of this interaction, rVHHs have a natural 'preference' to negatively modulate the catalytic activity of enzymes (Lauwereys et al., 1998; De Genst et al., 2006) . Nevertheless, it is not clear whether these results depend or not on the structure and chemical properties of the selected antigen. Furthermore, preliminary studies performed by our group on a single serum sample had suggested that polyclonal IgG 3 may be unable to inhibit In order to analyze whether significant quantities of HCAbs that negatively modulate enzymes can be obtained and purified from polyclonal sera, two enzymes were used to immunize llamas, and the modulatory response was characterized during the time-course of the immunization schedule. Total Ig titers indicate that all animals elicited a significant humoral immune response. Although the immunization schedule with APM yielded the expected ELISA titers, total Igs failed to modulate the catalytic activity of APM. In contrast, serum from animals immunized with CTX-M-2 produced a strong negative modulation of the enzyme, which progressed with time. The results obtained with the two groups of animals are not fully comparable, considering that they were immunized with different enzymes under different schedules; nevertheless, they indicate that both strategies yielded high titers of specific Abs. IgG 1 and IgG 3 were purified from all animals. ELISA titers showed that the total Ig titer is mainly due to IgG 1 , as the progress profile of this subisotype has similar pattern to total Igs. The modulatory capacity of purified Igs was then studied. These assays revealed that IgG 1 from animals immunized with APM produced a moderate positive modulation of the catalytic activity, and that IgG 3 failed to produce any enzyme modulation. In contrast, IgG 1 from animals immunized with CTX-M-2 produced a strong negative modulation and IgG 3 produced an intense positive modulation, which reverted to a subtle negative effect at the end of the immunization schedule.
The results presented in this work confirm our previous findings, now with two different enzymatic systems and during the whole immunization schedule. Total pHCAbs failed to inhibit the enzymes used as immunogens, either because no inhibitory HCAbs are produced or because these are produced in combination with activatory HCAbs. Indeed, total pHCAbs not only did not inhibit the enzymes but also activated one of them -in accordance with Saerens et al. (2004) , who reported prostate-specific antigen activation by rVHH -suggesting that production of polyclonal inhibitory HCAbs during in vivo immune responses is not a straightforward strategy as the production of rVHHs. Considering our results and recent reports on llamas and camels (van der Linden et al., 2000; Cook et al., 2010) , the nature of the selected antigen and the immunization plan could play a main role in biasing the humoral response toward conventional or HCAbs.
